Vectura Group (VEC) Given Hold Rating at Shore Capital
Vectura Group (LON:VEC)‘s stock had its “hold” rating restated by Shore Capital in a report released on Friday, ThisIsMoney.Co.Uk reports.
Several other equities analysts also recently issued reports on the company. Peel Hunt reissued a “hold” rating on shares of Vectura Group in a research report on Thursday, January 31st. JPMorgan Chase & Co. cut their target price on Vectura Group from GBX 110 ($1.44) to GBX 100 ($1.31) and set an “overweight” rating on the stock in a research report on Wednesday, April 3rd. Finally, Numis Securities reaffirmed a “buy” rating and issued a GBX 160 ($2.09) price target on shares of Vectura Group in a report on Wednesday, May 8th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Vectura Group currently has an average rating of “Buy” and a consensus price target of GBX 116.67 ($1.52).
LON VEC opened at GBX 78.46 ($1.03) on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.90 and a current ratio of 2.35. Vectura Group has a 1 year low of GBX 65.85 ($0.86) and a 1 year high of GBX 90.15 ($1.18). The firm has a market capitalization of $520.84 million and a P/E ratio of -5.94.
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
See Also: What is the Russell 2000 Index?
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.